Pro Medicus Limited (ASX:PME) shares were priced at $158.09 on 6 October 2026, down 0.73% on the day, and are down 48.03% over the past twelve months. The healthcare imaging software company announced its full year results for FY26 on 18 August 2026.

Across the broader market, the S&P/ASX 200 Health Care index [XHJ] (INDEXASX: XHJ) stood at 31,982.20, up 0.63% (+200.50 points) as of 6 October, and is down 16% over the past year. Meanwhile, the S&P/ASX 200 stood at 8,735.70, up 0.57% (+49.30 points) at the same time, and is down 2.74% over the year.

Business Model and Operational Footprint

Pro Medicus, founded in 1983, provides medical imaging software and services to hospitals, imaging centres and health care groups. Following its 2009 Acquisition of Visage Imaging, its Visage 7 suite forms the core of its platform, which can be deployed in public and private cloud environments. The company's offering includes RIS, PACS, artificial intelligence and e-health solutions, and it has offices in Melbourne, Berlin and San Diego.

Clients typically sign multi-year contracts, many for what the company calls the full stack of Viewer, Workflow and Archive. Customers range from smaller specialised health systems to large integrated delivery networks and academic medical centres in the United States. The company reported about 11% share of the US market and said it remains debt-free, with cash and other financial Assets of $252.3 million, up 19.7%.

Sector Dynamics

Diagnostic imaging software vendors sell into health systems that run multi-year procurement cycles, often through requests for proposals, and the company said many of its leads come from attendance at the annual RSNA conference in the United States. The release noted an increased number of inbound RFPs across all market segments.

Product scope is widening across the sector. Pro Medicus reported progress in cardiology, with clients including The Vancouver Clinic, TidalHealth, Medstar and Ohio State University taking its cardiology offering, and it launched digital pathology and AI-optimised reporting products during the year. Currency also matters: Revenue is earned largely offshore, and the release presents both reported and constant currency figures.

FY26 Results Update

Revenue was $261.7 million, up 22.9%. Underlying EBIT was $196.1 million, up 24.4%, and the EBIT Margin was 74.9%, up 90 basis points. Underlying NPAT was $144.7 million, up 24.1%, while reported NPAT was $265.3 million, up 130.3%. On a constant currency basis, underlying revenue was $273.5 million, up 28.4%, underlying EBIT was $206.0 million, up 30.6% and underlying NPAT was $154.5 million, up 32.5%. The company had stated a target of 30% increases in EBIT and NPAT and reported exceeding both on a constant currency basis. Over five years, revenue has increased 180%, a compound annual growth rate of 29%.

A fully franked final Dividend of 37 cents per share was declared, taking the total dividend for the year to 69 cents, up 25.5%.

The company announced ten new contracts worth a minimum of $407 million, including a ten-year $170 million contract with UC Health Colorado, a seven-year $90 million contract with Beth Israel Lahey Health and a five-year $44 million contract with Radiology Associates of North Texas. It renewed six of six contracts, worth $141 million on five-year terms, with higher minimums and increased fees per transaction. Renewals included Northwestern Health at $37 million, Medstar at $31 million and Allegheny at $28 million. In addition, $3 million of additions with existing clients were announced.

Pro Medicus completed 16 implementations in the period, including four Trinity Health cohorts and large implementations at the University of Colorado and BayCare. The company said the Trinity implementation is largely complete and that FY27 will carry a full year of contribution from these implementations.

Growth Catalysts and Critical Operating Risks

Items the company points to include the contribution from FY26 implementations in FY27 and beyond, a pipeline that, in the company's words, spans all market segments, the new digital pathology and AI-optimised reporting products, and cardiology adoption. The CEO, Dr Sam Hupert, said one platform and one Business model can address virtually every opportunity in diagnostic imaging, which he links to the company's total addressable market.

Operating risks in the release are largely implicit in the figures. Reported revenue and EBIT growth rates of 22.9% and 24.4% were lower than the constant currency rates of 28.4% and 30.6%, a gap that arises from year-on-year currency movements. The contracts listed in the release are mainly with United States health systems, and timing of contract signings and implementations affects when revenue is recognised. Reported NPAT growth of 130.3% differs materially from underlying NPAT growth of 24.1%, and the release does not itemise the difference in the text provided. Competition from other imaging platforms and procurement decisions by health systems are further variables.

The company's results also include several Balance Sheet and Capital items. It remains debt-free, with cash and other financial assets of $252.3 million. The release states that renewals set higher minimum fees and increased fees per transaction in every case, and that most new contracts were for the full Visage stack, with four clients also taking cardiology.

The Bottom Line

Pro Medicus reported FY26 revenue of $261.7 million, underlying NPAT of $144.7 million and a total dividend of 69 cents, with new contracts worth at least $407 million and six of six renewals. Its shares are down 48.03% over the year. Reported results were affected by currency movements, and the company expects the full contribution from FY26 implementations in FY27.